Vita Life Sciences Expects H1 Sales to Increase From a Year Earlier
MT Newswires Live
Jun 12
Vita Life Sciences (ASX:VLS) expects a pre-tax profit of AU$6.8 million to AU$7.3 million and sales of AU$46.3 million to AU$47.3 million for the half year ending June 30, according to a Friday filing with the Australian bourse.
For the first half of 2025, the company booked a pre-tax profit of AU$6.8 million on sales of AU$45.5 million, per the filing.
Vita Life Sciences said it expects "solid revenue growth" in the markets of Australia, Malaysia, and Singapore, partially offset by lower exports to China amid a shifting regulatory landscape and channel dynamics.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.